AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

BRCA Mutation Carriers' Platform a Multicenter Study

Recruitingn/aAges 18 Years - anyFemaleFondazione Policlinico Universitario Agostino Gem…
💬

In plain words

What the trial is, and whether it could suit you

Subjects who carry mutations in breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2 genes) are at higher risk of developing cancers. Despite the cumulative amount of evidence published in the literature in the last two decades, the management of BRCA mutation carriers is still not completely defined. Since the prevalence of the mutation is estimated to be 1:400 - 1:500 individuals, the total number of BRCA mutation carriers should be around 140.000 - 150.000 in the Italian population. It is estimated that 87% of women with BRCA mutations will experience, in their lifetime, a tumor with a genetic origin. About 20% of the 5200 ovarian cancer cases diagnosed each year in Italy has a genetic origin and could potentially be the object of primary prevention. To date, and to the best of our knowledge, a national prospective data collection on women with BRCA mutations has not been yet

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * All women who are 18 years of age or older; * All women who known to be carriers of a pathogenetic mutation class 4 and 5 of the International Agency of Research on Cancer classification) of the BRCA1 or BRCA2 genes. Exclusion Criteria: * Age \< 18 years old; * No pathogenetic mutation carriers.
💊

What it tests

  • Registration of clinical datas in the platform
📍

Where

40 sites
Malzoni Research Hospital
Avellino, Italy
Centro di Riferimento Oncologico IRCCS
Aviano, Italy
Università degli Studi di Bari "Aldo Moro"
Bari, Italy
IRCCS Istituto Tumori "Giovanni Paolo II"
Bari, Italy
ASST Papa Giovanni XXIII
Bergamo, Italy
L'Azienda ospedaliera per l'emergenza "Cannizzaro"
Catania, Italy
Azienda Ospedaliero Santa Croce e Carle
Cuneo, Italy
Presidio Ospedaliero Umberto I - ASP di Enna
Enna, Italy

…and 32 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy